2023 - Accurate Suicide Risk Detection with eC-SSRS Helps Ensure Safety of Trial Participants and Treatments in Oncology and Beyond

Protecting patients, compounds and proving benefits: How accurately accessing suicide risk detection with eC-SSRS/C-SSRS helps ensure clinical trial participants and their treatments remain safe in oncology and beyond.
Join esteemed speakers, Dr. Kelly Posner, Dr. John Greist and Libby Thomas for a deep dive into the nuances of accurately assessing suicide risk, including how the Columbia-Suicide Severity Rating Scale (Clinician reported: C-SSRS, patient self-report: eC-SSRS) is benefiting clinical trials by protecting patients, protecting drug compounds and more.
Patient safety is priority number one in clinical trials, making accurate and early detection of suicide risk essential. Drug development carries the risk of treatment-emergent depression and suicidal ideation for trial participants, and lack of suicide risk detection prior to treatment has led to drugs receiving “black-box warnings” by the US Food and Drug Administration (FDA). Extensive further testing was required to demonstrate the safety of the drugs before the warnings were removed, and many patients were delayed treatment during the testing period. Regularly administering the C-SSRS/eC-SSRS in clinical trials can help patients remain safe, and it can help prevent mislabeling drugs that do not carry these serious risks. When used at regular intervals, the C-SSRS/eC-SSRS can also be viewed in conjunction with treatment status and patient quality of life to assess levels of suicide risk in therapeutic areas traditionally hard to assess, such as oncology.
Join the featured speakers to explore the benefits of eC-SSRS/C-SSRS in protecting patients. Don’t miss this deep dive into suicide risk detection in oncology and beyond.